Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Français (Suisse)
Italiano
Nederlands (Nederland)
Nederlands (België)
MARKETS
Equities
United States
North America
Europe
Asia
Middle East
More Equities
Indexes
S&P 500
DOW JONES
NASDAQ 100
EURO STOXX 50
NIKKEI 225
More Indexes
Currency / Forex
USD / EUR
USD / CAD
USD / MXN
USD / BRL
USD / INR
More Currencies
Commodities
GOLD
CRUDE OIL (WTI)
CRUDE OIL (BRENT)
SILVER
PLATINUM
More Commodities
Cryptocurrencies
BITCOIN
ETHEREUM
Trackers & ETF
Rankings and News
Advanced Search
NEWS
Latest News
Companies
Markets
Economy
Currency / Forex
Commodities
Interest Rates
Finance Pro.
Business Leaders
Cryptocurrencies
Cybersecurity
Economic Calendar
Listed companies
Analyst Reco.
Rumors
IPOs
Capital Markets Transactions
New Contracts
Profit Warnings
Appointments
Press Releases
Events
Security Transactions
Financial Calendar
Sector News
Energy
Basic Materials
Industrials
Consumer Cyclical
Consumer Non-Cyclical
Financials
Healthcare
Technology
Real Estate
Utilities
ANALYSIS
All Analysis
Must Read
Daily Briefing
Weekly market update
Stock Trading Strategies
STOCK PICKS
All Stock Picks
Subscribe
PORTFOLIOS
My Portfolio
Virtual Portfolios
MarketScreener Portfolios
USA Portfolio
European Portfolio
Asian Portfolio
WATCHLISTS
My Watchlists
Watchlists
My previous session
My most visited
Most popular
Investment Style
Trend-Following Stocks
Undervalued stocks
ESG stocks
Growth stocks
Yield stocks
Quality stocks
Investment Themes
Europe's family businesses
Boats
Biotechnology
The Vegan Market
Water
Luxury
RANKINGS
Top News
Most Read News
Hot News
Top Fundamentals
Top Capitalization
Top Yield
Top PER
Top Consensus
Top Fundamentals
Top ranking ESG
Top Technicals
Top RSI
Unusual volumes
Top Gaps
Top STIM
Breakouts
Trends
Top Movers
Top USA
Top Canada
Top U.K.
Top Germany
Top Europe
Top Asia
SCREENERS
Investment Themes
Boats
Gold and Silver
Place your bets
Artificial Intelligence
Ageing Population
Smart City
Technical Rankings
Oversold stocks
Overbought stocks
Close to resistance
Close to support
Accumulation Phases
Most volatile stocks
Fundamental Rankings
Top Investor Rating
Top Trading Rating
Top Consensus
Growth stocks
Yield stocks
Low valuations
Stock Screener Home
My Screeners
All my stocks
Watchlists
Virtual Portfolios
TOOLS
MarketScreener tools
Stock Screener
iPhone App
Expert tools
Stock Screener PRO
Portfolio Creator
Event Screener
Tools
Dynamic Chart
Financial Calendar
Economic Calendar
Sector Research
Currency Converter
ProRealTime Trading
OUR SERVICES
MarketScreener Portfolios
European Portfolio
USA Portfolio
Asian Portfolio
Our Stock Picks
Thematic Investment Lists
Stock Screener
Homepage
Equities
United Kingdom
London Stock Exchange
GlaxoSmithKline plc
News
Summary
GSK
GB0009252882
GLAXOSMITHKLINE PLC
(GSK)
Add to my list
Report
Delayed London Stock Exchange -
05/20 11:36:48 am EDT
1764.00
GBX
+1.87%
05/20
Deutsche Bank Keeps GSK At Hold, Boosts PT
MT
05/19
GLAXOSMITHKLINE
: Deutsche Bank remains Neutral
MD
05/19
GLAXOSMITHKLINE PLC
: Ex-dividend day for interim dividend
FA
Summary
Quotes
Charts
News
Ratings
Calendar
Company
Financials
Consensus
Revisions
Summary
Most relevant
All News
Analyst Reco.
Other languages
Press Releases
Official Publications
Sector news
MarketScreener Strategies
GSK Ventures into Bioelectronic Therapies For Arthritis With Study Launches
01/26/2022 | 10:16pm EDT
Send by mail :
Name :
First name :
From
*
:
To
*
:
(You can enter multiple email addresses separated by commas)
Message :
*
Required fields
© MT Newswires 2022
Stocks mentioned in the article
Change
Last
1st jan.
ALPHABET INC.
-1.34%
2178.16
-24.81%
GLAXOSMITHKLINE PLC
1.87%
1764
9.80%
All news about GLAXOSMITHKLINE PLC
05/20
Deutsche Bank Keeps GSK At Hold, Boosts PT
MT
05/19
GLAXOSMITHKLINE
: Deutsche Bank remains Neutral
MD
05/19
GLAXOSMITHKLINE PLC
: Ex-dividend day for interim dividend
FA
05/18
S&P Maintains GSK's Ratings, Stable Outlook on Expected Post-Demerger Recovery
MT
05/17
FTSE 100 lags European peers on strong pound
RE
05/17
GlaxoSmithKline Pharmaceuticals Sees Surge in Fiscal Q4 Consolidated Net Profit
MT
05/16
Glaxosmithkline Confirms It Has Changed Its Name To GSK PLC
RE
05/16
GlaxoSmithKline Adopts Shortened GSK Name
MT
05/16
GlaxoSmithKline plc has Changed its Name to GSK plc
CI
05/16
SocGen Lifts GlaxoSmithKline's PT, Keeps Buy Rating
MT
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
05/20
Deutsche Bank Keeps GSK At Hold, Boosts PT
MT
05/19
GLAXOSMITHKLINE
: Deutsche Bank remains Neutral
MD
05/16
SocGen Lifts GlaxoSmithKline's PT, Keeps Buy Rating
MT
More recommendations
Financials
GBP
USD
Sales 2022
36 543 M
45 551 M
45 551 M
Net income 2022
5 289 M
6 593 M
6 593 M
Net Debt 2022
17 655 M
22 006 M
22 006 M
P/E ratio 2022
16,6x
Yield 2022
2,98%
Capitalization
89 279 M
111 B
111 B
EV / Sales 2022
2,93x
EV / Sales 2023
2,78x
Nbr of Employees
90 096
Free-Float
93,6%
More Financials
Chart GLAXOSMITHKLINE PLC
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short Term
Mid-Term
Long Term
Trends
Neutral
Bullish
Bullish
Technical analysis
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
More Financials
Consensus
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1 764,00 GBX
Average target price
1 865,77 GBX
Spread / Average Target
5,77%
Consensus
EPS Revisions
Please enable JavaScript in your browser's settings to use dynamic charts.
More Estimates Revisions
Managers and Directors
Emma N. Walmsley
Chief Executive Officer & Executive Director
Iain James Mackay
Chief Financial Officer & Executive Director
Jonathan Richard Symonds
Non-Executive Chairman
Hal V. Barron
Executive Director & Chief Scientific Officer
Jon Ellis
VP & Head-Technology Business Development
More about the company
Sector and Competitors
1st jan.
Capi. (M$)
GLAXOSMITHKLINE PLC
9.80%
111 286
JOHNSON & JOHNSON
1.68%
465 705
PFIZER, INC.
-11.14%
294 404
ELI LILLY AND COMPANY
8.19%
269 013
ABBVIE INC.
11.53%
266 851
ROCHE HOLDING AG
-15.67%
266 707
More Results
Slave